• 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167178
  • 2
    Haylen BT, de Ridder D, Freeman RM et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 2010; 21: 526
  • 3
    Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6: S574579
  • 4
    Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 13061314; discussion 1314–5
  • 5
    Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760766
  • 6
    Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327336
  • 7
    Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543562
  • 8
    Chapple CR, Rosenberg MT, Brenes FJ. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 2009; 104: 960967
  • 9
    Cardozo L, Hessdorfer E, Milani R et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 11201127
  • 10
    Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464470
  • 11
    Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73: 1418
  • 12
    Zinner N, Kobashi KC, Ebinger U et al. Darifenacin treatment for overactive bladder in patients who expression dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract 2008; 62: 16391640
  • 13
    Staskin D, Khullar V, Michel M et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodynam 2011; 30: 14801485
  • 14
    Wyndaele JJ, Goldfischer ER, Morrow JD et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009; 63: 560567
  • 15
    Cardozo L, Mikulas J, Amarenco G et al. Total urgency score (TUS) as a measure of frequency and urgency in SUNRISE. Urology 2010; 76 (Suppl. 3a): 592. Abstract UP-2.35
  • 16
    Chapple C, Fila R, Gorilovsky L et al. The STAR study: analysis of symptom severity and treatment response in overactive bladder. Int Urogynecol J 2006; 17 (Suppl. 2): Abstr 380, S88
  • 17
    Vardy MD, Mitcheson HD, Samuels TA et al. Effetcs of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT – a double-blind, placebo-controlled trial. Int J Clin Pract 2009; 63: 17021714